• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Symposium on Hormonal Carcinogenesis >Gonadotrophin Releasing Hormone-Based Vaccine, an Effective Candidate for Prostate Cancer and Other Hormone-sensitive Neoplasms
【24h】

Gonadotrophin Releasing Hormone-Based Vaccine, an Effective Candidate for Prostate Cancer and Other Hormone-sensitive Neoplasms

机译：促性腺激素释放基于激素的疫苗，是前列腺癌的有效候选者和其他激素敏感的肿瘤

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prostate growth, development, functions, and neoplastic transformation is androgen dependent. Estrogens have similar effects in the ovary and breast. Previous studies using gonadotrophin releasing hormone (GnRH/LHRH) vaccines have shown the usefulness of immunization against this hormone in prostate (PC) and breast cancer (BC). We have synthesized a peptide mutated at position 6 and attached to the 830-844 tetanic toxoid (TT) helper T cell sequence in the same synthesis process. After repeated pig immunizations, we have demonstrated a vaccine that significantly decreased testes size (p < 0.001), prostate (p < 0.01), seminal vesicles (p < 0.01), and testosterone (T) castration [0.05 nM ml"1 (p<0. 01)]. Similar results were obtained in adult male and female healthy dogs and Macacafascicularis models. These data indicate that this GnRHml-TT vaccine is safe and able to induce significant tumor growth inhibition in the Dunning R3327-H rat androgen responsive prostate tumor model. In these rats, the immunization induced high anti-GnRH titers concomitant with T castration reduction (p < 0.01) in 90% of the animals tested. In addition, 70% of the responders exhibited tumor growth inhibition (p = 0.02) and a survival rate approximately three times longer that those of untreated rats. These data indicate that GnRHml-TT vaccine may be a potential candidate in the treatment of PC, BC, and other hormone-dependent cancers.
机译：前列腺生长，发育，功能和肿瘤转化是雄激素依赖性。雌激素在卵巢和乳房中具有类似的效果。以前使用促性腺激素释放激素（GnRH / LHRH）疫苗的研究表明，对前列腺（PC）和乳腺癌（BC）中这种激素免疫的有用性。我们在相同的合成过程中合成了在位置6处的肽突变并连接到830-844滴注毒素T细胞序列。经过重复的猪免疫后，我们已经证明了一种显着降低的疫苗（P <0.001），前列腺囊泡（P <0.01），睾酮（P <0.01）和睾酮（P <0.01）呈血管[0.05 nm mL] 1（P <0.01）。在成年男性和女性健康犬和Macacafascicularis模型中获得了类似的结果。这些数据表明该GNRHML-TT疫苗是安全的，并且能够在令人垂涎的R3327-H大鼠androgen响应中诱导显着的肿瘤生长抑制前列腺肿瘤模型。在这些大鼠中，免疫诱导的高抗GNRH滴度伴随着测试的90％的动物阉割减少（P <0.01）。此外，70％的响应者表现出肿瘤生长抑制（P = 0.02 ）和生存率约为3倍，即未经处理的大鼠的时间越长。这些数据表明GNRHML-TT疫苗可以是治疗PC，BC和其他激素依赖性癌症的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号